Does Beovu help with wet AMD?

Beovu (brolucizumab-dbll) is used to treat wet AMD (also called neovascular age-related macular degeneration) in adults. Two trials (HAWK and Harrier) have reported the benefits with Beovu are similar to those seen with Eylea. Improvements in visual acuity (the ability to see more clearly) started after the first injection of Beovu and were noticeable within 4 weeks, reached their maximum at 48 weeks, and persisted for at least 2 years (the length of the trial).

Beovu is an injection that is administered directly into the eye by a qualified physician. The usual dosage is one injection approximately monthly for the first three doses, then 8 to 12 weekly thereafter.

Wet ADM occurs when abnormal, leaky blood vessels grow under your macula. The macula is the part of your retina at the back of your eye and it is responsible for your central vision. The leaky blood vessels can cause scaring on your macula, leading to blurry vision, wavy lines in your vision, muted colors and blind spots.